Histamine H3 receptor antagonists: preclinical promise for treating obesity and cognitive disorders.
about
The histamine H3 receptor: an attractive target for the treatment of cognitive disordersActivation of peripheral and spinal histamine H3 receptors inhibits formalin-induced inflammation and nociception, respectivelyMonoaminergic and Histaminergic Strategies and Treatments in Brain DiseasesHistamine H3 receptors and its antagonism as a novel mechanism for antipsychotic effect: a current preclinical & clinical perspectiveMultifunctional receptor-directed drugs for disorders of the central nervous systemIdentification and characterization of ZEL-H16 as a novel agonist of the histamine H3 receptorCognitive control deficits in schizophrenia: mechanisms and meaningZebrafish: An in vivo model for the study of neurological diseases.Recent advances in Tourette syndrome.Ciproxifan, an H3 receptor antagonist, alleviates hyperactivity and cognitive deficits in the APP Tg2576 mouse model of Alzheimer's diseaseHistamine H1 receptor antagonist cetirizine impairs working memory processing speed, but not episodic memory.H3 receptors and pain modulation: peripheral, spinal, and brain interactions.The genetics of Tourette disorderCurrent and future drug targets in weight managementRecent development of multifunctional agents as potential drug candidates for the treatment of Alzheimer's disease.CC12, a high-affinity ligand for [3H]cimetidine binding, is an improgan antagonist.Translational and Early Phase Strategies for Treatment Development: Report of ISCTM Autumn 2013 Symposium.Histamine-induced itch and its relationship with pain.Histamine H3 receptor ligands break ground in a remarkable plethora of therapeutic areas.Effects of L-histidine depletion and L-tyrosine/L-phenylalanine depletion on sensory and motor processes in healthy volunteers.Histamine H1 receptor blockade predominantly impairs sensory processes in human sensorimotor performance.Ligand autoradiographical quantification of histamine H3 receptor in human dementia with Lewy bodies.Histamine H4 receptor ligands and their potential therapeutic applications.Recent advances in histamine H3 receptor antagonists/inverse agonists.Immunomodulation using agonists and antagonists: potential clinical applications.Advances in the molecular modeling and quantitative structure-activity relationship-based design for antihistamines.Procognitive properties of drugs with single and multitargeting H3 receptor antagonist activities.Synthesis, biological evaluation, and computational studies of Tri- and tetracyclic nitrogen-bridgehead compounds as potent dual-acting AChE inhibitors and hH3 receptor antagonists.Rational Modification of the Biological Profile of GPCR Ligands through Combination with Other Biologically Active Moieties.Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder.Discovery of a potent thiadiazole class of histamine h3 receptor antagonist for the treatment of diabetesThe histamine autoreceptor is a short isoform of the H₃ receptor.Non-imidazole histamine H3 ligands: part V. synthesis and preliminary pharmacological investigation of 1-[2-thiazol-4-yl- and 1-[2-thiazol-5-yl-(2-aminoethyl)]-4-n-propylpiperazine derivatives.Comparison of Different 2D and 3D-QSAR Methods on Activity Prediction of Histamine H3 Receptor Antagonists.Histamine induces the expression of uncoupling protein 2 (UCP2) and acid-binding protein (aP2) in white adipocytes.Preclinical evaluation of non-imidazole histamine H3 receptor antagonists in comparison to atypical antipsychotics for the treatment of cognitive deficits associated with schizophrenia.A mathematical model for histamine synthesis, release, and control in varicosities.Assessment of the abuse liability of ABT-288, a novel histamine H₃ receptor antagonist.Determination of receptor occupancy in the presence of mass dose: [11C]GSK189254 PET imaging of histamine H3 receptor occupancy by PF-03654746.
P2860
Q24654788-3129FEFF-C6B0-4E4B-B113-B51C303B3CFAQ24683489-77DF479F-8AF0-44E9-91F6-263DF76E81A4Q28066691-47B0226A-F50E-4977-AE33-79FDF22A0B91Q28073102-E5446444-E8E6-495F-99E0-3C7DBDD484ADQ28305096-A413EE6E-D6F9-46D6-868B-C007B726AB54Q28481970-E075FAF2-3A81-4902-97B7-6E278EA1A462Q30476447-A50FBD8C-9510-4D98-8A41-E5E891BF6CDFQ30493208-3CC22901-BA11-48E8-96A3-6332EC27DCE1Q33786160-AD0E85E7-4D7B-4848-AC10-E3903FD7B7EAQ34149546-78BFB404-71A1-4276-A4B7-1EFA963E2702Q34339795-045F7FA6-34DC-4A24-AC72-F2325F40250FQ34458579-73FACB50-3B39-408D-9577-AF6FF4AE2CB1Q35007575-BB1C4CD1-2ECE-44EE-AC9C-E025507B35FCQ35089784-9CCB2FC7-C418-4758-A967-9427E82D87B9Q35617556-6409776E-CE57-4435-9517-D5408D02EC70Q35842760-3DD0D3B2-E64B-4285-BBC1-81AD39E8A875Q36063620-4503DCE3-FF12-4C90-8056-69BD2049F39FQ36844223-85EEB8EA-5358-4A04-862D-7A5497F3A4AEQ36861579-5A9FDDDC-D3CF-43F2-9A72-AA9976339CCDQ37230871-4D25CD67-96A9-4123-B2F5-B545D15457FBQ37230876-A557AB9C-4155-4FDB-9C22-C639D46EFE06Q37420711-CAABFD17-557B-40B2-BC8F-74D9716A940BQ37481276-C12E640F-67F1-4403-954C-1F08BB7C089EQ37780549-F71A9F45-D94D-4F7D-8AE6-C601F168F288Q37965728-7778AFF5-F92E-4AA1-A939-10FF5617A001Q38071647-791F168D-9561-4489-9BB2-55785224E5F0Q38212433-A3CCD7DA-44B6-4A41-8B1F-112914116831Q38419860-1BFDAE7D-EC88-4BBA-A763-3A7077B4EB91Q38458891-D5400893-23A1-4D45-A0F9-650E93269A6AQ38463350-02FD8526-9283-4F49-A7F7-1CA16B74E153Q39731080-0E321891-8DCC-44D9-BED7-CE09A43E9FD5Q41871692-DABC4C4F-5742-4B61-96C3-A766D5868BF0Q42012445-FB516DB7-51CC-4505-8ACE-239F166E988AQ42768396-59604B1A-817A-45FA-A307-96456C7F41CFQ42826504-B8BC0F3F-A7F0-4490-B128-836AF83C5355Q46038979-ADE4AF5F-7BE0-4FC0-9E36-141982547232Q47099150-7D4FF0F5-11C3-4458-A0FE-E3988F485D2FQ48030646-F587FBD2-9638-4EE5-ACBF-492550865A28Q50641608-B9F3AB5F-14ED-46E1-9B55-C1E161FACC3C
P2860
Histamine H3 receptor antagonists: preclinical promise for treating obesity and cognitive disorders.
description
2006 nî lūn-bûn
@nan
2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Histamine H3 receptor antagoni ...... esity and cognitive disorders.
@ast
Histamine H3 receptor antagoni ...... esity and cognitive disorders.
@en
Histamine H3 receptor antagoni ...... esity and cognitive disorders.
@nl
type
label
Histamine H3 receptor antagoni ...... esity and cognitive disorders.
@ast
Histamine H3 receptor antagoni ...... esity and cognitive disorders.
@en
Histamine H3 receptor antagoni ...... esity and cognitive disorders.
@nl
prefLabel
Histamine H3 receptor antagoni ...... esity and cognitive disorders.
@ast
Histamine H3 receptor antagoni ...... esity and cognitive disorders.
@en
Histamine H3 receptor antagoni ...... esity and cognitive disorders.
@nl
P2093
P356
P1476
Histamine H3 receptor antagoni ...... esity and cognitive disorders.
@en
P2093
Gerard B Fox
Marlon D Cowart
Timothy A Esbenshade
P304
P356
10.1124/MI.6.2.5
P577
2006-04-01T00:00:00Z